课题基金 / 基金详情

Molecular Heterogeneity of Inflammation and Growth Factor Pathways in Sporadic and Syndromic Colon Cancers: Implications for Prevention and Therapeutic TrialsPOP: 09/15/2014-09/14/2015

Molecular Heterogeneity of Inflammation and Growth Factor Pathways in Sporadic and Syndromic Colon Cancers: Implications for Prevention and Therapeutic TrialsPOP: 09/15/2014-09/14/2015
散发性和综合征性结肠癌中炎症和生长因子途径的分子异质性：对预防和治疗试验的影响POP：09/15/2014-09/14/2015
批准号：
8944482
负责人：
CHINTHALAPALLY RAO
金额：
$48.2万
依托单位：
--
依托单位国家：
美国
项目类别：
财政年份：
2014
资助国家：
美国
项目状态：
已结题
起止时间：
2014-09-15 至 2015-09-14
来源：
https://reporter.nih.gov/project-details/8944482
关键词：
AddressAftercareCandidate Disease GeneChemopreventionChemopreventive AgentClinical ChemopreventionClinical TrialsColon CarcinomaColonic PolypsContractorContractsDrug effect disorderEnsureErlotinibGene ExpressionGenesGoalsGrowth FactorHeterogeneityHistologicIndividualInflammationMolecularMucous MembraneMutateMutationNormal tissue morphologyParticipantPathway interactionsPatientsPhase II Clinical TrialsPlacebo ControlPolypsPreventionProcessRandomizedResistanceSamplingSourceSulindacTherapeuticTissuescolon carcinogenesisgenetic analysisgenetic pedigreeoverexpression

项目摘要

项目成果

CHINTHALAPALLY RAO的其他基金

相似基金

相关文献

中文摘要
翻译
该合同是对治疗前和治疗后的十二指肠和结肠息肉以及来自FAP/AFAP参与者的组织学正常组织进行分子分析，这些参与者正在进行一项随机、安慰剂对照的II期临床试验，该试验使用舒林他和厄洛替尼或其他适当选择的化学预防药物。最终目标应该是将含有这些标记物的途径与结肠癌发生机制和抑制这一过程的药物作用联系起来。
英文摘要
The contract is to perform molecular analyses on pre- and post-treatment duodenal and colonic polyps as well as histologically normal tissue from FAP/AFAP participants in an existing randomized, placebo-controlled, phase II clinical trial of sulindac and erlotinib or other appropriately selected chemopreventive agents. The ultimate goal shall be to correlate the pathways that contain these markers with mechanisms of colon carcinogenesis and of drug action in inhibiting this process.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Base Title: PREVENT Preclinical Drug Development Program: Preclinical Efficacy and Intermediate Endpoint BiomarkersTask Order Title: Colorectal Cancer (CRC) Prevention by TPST-1495 in PIRC rat mod
TITLE: BLADDER CANCER CHEMOPREVENTION USING THE ANDROGEN RECEPTOR INHIBITOR APALUTAMIDE
TASK ORDER TITLE: PREVENTING LUNG ADENOCARCINOMA (LUAD) USING TRAIL INDUCING AGENT, ONC201BASE CONTRACT TITLE: PREVENT PRECLINICAL DRUG DEVELOPMENT
BASE TITLE: PREVENT PRECLINICAL DRUG DEVELOPMENT PROGRAM: PRECLINICAL EFFICACY AND INTERMEDIATE BIOMARKERSTASK ORDER TITLE: PREVENTING FAP-CRC USING
海外基金